Compare Merck & Co., Inc. (MRK) vs IAC/Interactivecorp (PPLI) Price & Performance

Merck & Co., Inc.Trade

IAC/InteractivecorpTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs IAC/Interactivecorp — how do they compare? Merck & Co., Inc. trades at $126.01 (market cap $307.25B), while IAC/Interactivecorp trades at $44.87 (market cap $3.32B). The key difference: Merck & Co., Inc. is far larger — about 92.5× IAC/Interactivecorp's market cap, and Merck & Co., Inc. pays a 2.73% dividend while IAC/Interactivecorp pays none. Which is the better fit depends on your goals.

	MRK	PPLI
Market Cap	$307.25B	$3.32B
Sector	Health	Media
52-Week High	$129.52	$47.62
52-Week Low	$77.60	$31.52
Enterprise Value	$350.66B	$3.63B
Dividend Yield	2.73%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamentals including a net income margin of 13.59% and ROE of 18.97%. Recent earnings beats and the acquisition of Terns Pharmaceuticals for approximately $6.7 billion highlight strategic growth initiatives. The stock is supported by a consensus analyst price target of $137.30, indicating potential upside from current levels.

The outlook for Merck is positive, driven by robust profitability, strategic acquisitions, and analyst confidence. Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06% in 2025, and competitive pressures in the oncology space. Investors should weigh strong cash flow generation against execution risks in integrating recent acquisitions.

IAC/Interactivecorp

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MRK

Over 180 companies develop 200+ PD-1/PD-L1 inhibitors, reshaping cancer treatment landscape.Delveinsight · 4 hours agoBullish Schwab U.S. Dividend Equity ETF (SCHD) remains a Buy for strong dividends and growth potential.Seeking Alpha · 1 day agoBullish Merck rated Strong Buy on oncology growth and new LIPFENDRA launch for cholesterol controlSeeking Alpha · 4 days agoBullish View details →

PPLI

People Inc. seen undervalued with 35% upside potential from BetMGM growth and asset salesSeeking Alpha · 4 days agoBullish View details →

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

About IAC/Interactivecorp

IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.